Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 156,079 229,843 273,203 611,547
Total Sell Value $13,472,349 $20,340,408 $24,241,430 $58,103,504
Total People Sold 5 5 6 7
Total Sell Transactions 13 19 25 55
End Date 2024-02-22 2023-11-21 2023-05-23 2022-05-23

   
Records found: 1313
  Page 16 of 53  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-30 4 A $62.59 $21,217 D/D 339 298,552     -
   Davis George Eric EVP, General Counsel   •       –      –    2020-04-30 4 A $62.59 $21,217 D/D 339 78,181     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-28 4 AS $97.58 $1,951,600 D/D (20,000) 298,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-28 4 OE $21.51 $430,200 D/D 20,000 318,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-27 4 AS $97.73 $1,954,600 D/D (20,000) 298,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-27 4 OE $21.51 $430,200 D/D 20,000 318,213     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-04-24 4 AS $95.34 $1,917,617 D/D (20,000) 102,656     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-04-20 4 AS $90.00 $1,549,170 D/D (17,213) 122,656     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-09 4 AS $79.06 $790,600 D/D (10,000) 298,213     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-09 4 OE $21.51 $215,100 D/D 10,000 308,213     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-04-08 4 AS $79.98 $192,512 D/D (2,407) 63,064     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-04-07 4 OE $26.49 $26,490 D/D 1,000 298,213     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-04-01 4 AS $82.00 $126,034 D/D (1,537) 65,471     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-03-25 4 AS $78.47 $126,964 D/D (1,618) 67,008     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-03-24 4 AS $74.36 $151,769 D/D (2,041) 68,626     -
   Mueller Brian SVP, Acting CFO   •       –      –    2020-03-20 4 D $73.05 $30,243 D/D (414) 24,781     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2020-03-20 4 D $73.05 $959,000 D/D (13,128) 297,213     -
   Davis George Eric EVP, General Counsel   •       –      –    2020-03-20 4 D $73.05 $241,722 D/D (3,309) 77,842     -
   Baffi Robert President, Global Mfg/Tech Ops   •       –      –    2020-03-20 4 D $73.05 $255,748 D/D (3,501) 117,138     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2020-03-20 4 D $73.05 $426,320 D/D (5,836) 139,869     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2020-03-20 4 D $73.05 $262,907 D/D (3,599) 70,667     -
   Lawlis V Bryan Director   –       •      –    2020-03-17 4 AS $75.39 $282,713 D/D (3,750) 18,980     -
   Lawlis V Bryan Director   –       •      –    2020-03-17 4 OE $21.51 $80,663 D/D 3,750 22,730     -
   Lawlis V Bryan Director   –       •      –    2020-03-16 4 AS $76.52 $352,757 D/D (4,610) 18,980     -
   Mueller Brian SVP, Acting CFO   •       –      –    2020-03-16 4 A $0.00 $0 D/D 6,730 25,195     -
  1313 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 16 of 53
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us